Stocks · News reference
Pharvaris Announces Statistically Significant And Clinically Meaningful Topline Results From Its CHAPTER-3 Pivotal Phase 3 Study Evaluating Deucrictibant Extended-Release Tablet For Prevention Of HAE Attacks; Primary Endpoint And All Secondary Efficacy Endpoints Were Met With Statistical Significance
Primary endpoint met: 83% attack rate reduction versus placebo (p<0.0001) in the first and only prophylaxis Phase 3 study in all three types of HAE87% attack rate reduction versus placebo observed in people with HAE
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HC Wainwright & Co. Reiterates Buy on Pharvaris, Maintains $60 Price Target
Roivant Sciences, Pharvaris, IonQ And Other Big Stocks Moving Higher On Tuesday
U.S. stocks fell Tuesday, but Roivant surged 16% on positive PH-ILD trial data. Pharvaris, Solaris, IonQ and quantum stocks also posted strong gains.
Why Is Pharvaris Stock Soaring Tuesday?
Pharvaris (PHVS) stock surges 17% on positive Phase 3 HAE trial data. Deucrictibant XR reduced monthly attacks up to 87%.